Kilgore K S, Friedrichs G S, Johnson C R, Schasteen C S, Riley D P, Weiss R H, Ryan U, Lucchesi B R
Department of Pharmacology, University of Michigan Medical School, Ann Arbor 48109-0626.
J Mol Cell Cardiol. 1994 Aug;26(8):995-1006. doi: 10.1006/jmcc.1994.1120.
An experimental model of myocardial ischemia/reperfusion injury was used to assess the cardioprotective effects of SC-52608, a low molecular weight superoxide dismutase mimetic. Langendorff perfused rabbit isolated hearts were subjected to 30 min of global ischemia followed by 45 min of reperfusion. Hearts perfused in the presence of 20 microM SC-52608 exhibited a decrease in the release of creatine kinase and intracellular potassium compared to hearts receiving vehicle (control). A progressive increase in left ventricular end-diastolic pressure developed upon reperfusion in all hearts, but was significantly greater in control hearts when compared to hearts treated with SC-52608 (P < 0.05). In addition, results obtained with a radiolabeled monoclonal antibody to the intracellular protein myosin, indicate an increased degree of irreversible damage in vehicle-treated hearts. Myocardial protection was not significant in an additional group of hearts treated with 10 microM SC-52608. The hemodynamic, biochemical, morphological, as well as the antimyosin binding data, demonstrate that pretreatment with SC-52608 protects the myocardium from damage associated with global ischemia and reperfusion. The mechanism by which SC-52608 mediates the observed protective effect is most likely related to its ability to scavenge superoxide.
采用心肌缺血/再灌注损伤实验模型来评估低分子量超氧化物歧化酶模拟物SC - 52608的心脏保护作用。对经Langendorff灌流的兔离体心脏进行30分钟全心缺血,随后再灌注45分钟。与接受赋形剂(对照)的心脏相比,在20微摩尔SC - 52608存在下灌流的心脏肌酸激酶释放和细胞内钾含量降低。所有心脏在再灌注时左心室舒张末期压力均逐渐升高,但与用SC - 52608处理的心脏相比,对照心脏中的升高更为显著(P < 0.05)。此外,用针对细胞内蛋白肌球蛋白的放射性标记单克隆抗体获得的结果表明,赋形剂处理的心脏中不可逆损伤程度增加。在用10微摩尔SC - 52608处理的另一组心脏中,心肌保护作用不显著。血流动力学、生化、形态学以及抗肌球蛋白结合数据表明,SC - 52608预处理可保护心肌免受与全心缺血和再灌注相关的损伤。SC - 52608介导观察到的保护作用的机制很可能与其清除超氧化物的能力有关。